Coating Tablet OEM/ODM Premix Service
If you’ve been watching the nutraceutical aisle lately, you’ll have noticed the quiet arms race: cleaner labels, shinier coats, faster dissolves, fewer complaints. To be honest, a lot of teams are scrambling to balance stability, taste-masking, and cGMP speed. That’s exactly where Coating Tablet OEM/ODM Premix Service earns its keep—an integrated route from premix to coated tablet that doesn’t feel stitched together.
Why now: market pulse
Brands want science-backed coatings (HPMC, PVA, or enteric polymers) with natural colors, compliant with USP/EP and retailer audits. Actually, many customers say the “last mile” issues—chipping, poor gloss, sulfur smells—are what hurt repeat purchase. We see rising demand for sugar-free film coats, plant-based glossing agents, and rapid scale-up.
What’s in the service
- Formulation-to-finish: premix → granulation → compression → coating → pack-out.
- Capacity (annual): Tablets 300,000,000; Hard capsules 500,000,000; Granule/Coated ≈ 2,500 MT; Premix ≈ 3,500 MT.
- Scope: Botanical extracts, minerals, vitamins, amino acids; taste-masking, moisture-barrier, enteric or controlled release.
- Origin: Building 23B1, No.2 Yuanboyuan St., Zhengding Area of China (Hebei) Pilot Free Trade Zone.
Key specifications (typical, real-world use may vary)
| Coating systems | HPMC/PVA immediate-release; Enteric (HPMCP, HPMC-AS); Moisture-barrier; Natural-color options |
| Premix granularity | D90 ≈ 250–400 μm; bulk density 0.45–0.65 g/mL |
| Tablet targets | Hardness 6–12 kp; Friability ≤0.8%; Disintegration ≤15 min (IR) |
| Dissolution | ≥85% in 30 min (USP , IR); Enteric: acid stage Q=0, buffer stage ≥80%/45–60 min |
| Microbiology | TPC ≤10^3 CFU/g; Yeast/Mold ≤10^2 CFU/g; Pathogens: absent |
| Heavy metals | ICH Q3D compliant (μg/day basis) |
| Shelf life | 24–36 months in HDPE/alu-alu, controlled RH |
| Certifications | GMP (21 CFR Part 111), ISO 9001, ISO 22000/FSSC, Halal/Kosher |
Process flow (packed but practical)
- Materials: botanical extracts, minerals, binders, disintegrants, lubricants; coating polymers + plasticizers; natural pigments.
- Methods: dry/wet granulation; fluid-bed or high-shear; compression with in-line weight control.
- Coating: perforated pan, validated spray rate/atomization; weight gain ~2–6% (IR) or 6–12% (enteric).
- Testing: USP ///, moisture (LOD), assay by HPLC/ICP-MS, uniformity, stability (ICH Q1A).
- QA/QC: ISO/IEC 17025-partnered labs; traceability LIMS; retain samples per SOP.
- Packaging: HDPE, alu-alu, blister PVC/PVDC; desiccant and light shields as needed.
- Industries: nutraceuticals, sports nutrition, herbal/traditional, women’s health, immunity, bone & joint, cognitive.
Vendor comparison (quick look)
| Factor | Finutra Coating Tablet OEM/ODM Premix Service | Vendor A (global CMO) | Vendor B (local blender) |
|---|---|---|---|
| Lead time | ≈4–8 weeks | 8–14 weeks | 2–6 weeks (limited scale) |
| Scale-up risk | Low (pilot → commercial on-site) | Medium | High |
| Coating menu | IR, moisture-barrier, enteric, natural colors | Strong but pricier | Basic IR |
| Compliance | GMP, ISO 9001/22000, Halal/Kosher | GMP, ISO | Varies |
Customization, plus a few real-world notes
- Clean-label palette: iron oxides, calcium carbonate, spirulina; titanium-dioxide-free on request.
- Enteric strategies: HPMCP/HPMC-AS with targeted pH threshold ≈5.5–6.0; great for fish oil odor control too.
- Taste and odor: botanical actives get PVA/HPMC film + flavor topcoat—surprisingly effective in stability pulls.
- Service life: pilot lots indicate 24–36 months at 25°C/60%RH; stress 40°C/75%RH supports label claims with moisture-barrier coats.
Case snippets
Case A—Ashwagandha IR tablet: revamped with HPMC/PVA film; friability dropped from 1.2% to 0.4%, complaints on “powdery feel” basically vanished. “Looks premium now,” the brand told us.
Case B—High-calcium chewable: moisture-barrier coat reduced caking and label claim drift (Ca assay within 98–101% over 6 months, accelerated). Retail returns? Near-zero in the next cycle.
Compliance anchor points: cGMP (21 CFR Part 111), USP //, ICH Q3D for elemental impurities, stability by ICH Q1A. Audits welcome; third-party testing available.
References
- USP General Chapters Dissolution; Uniformity of Dosage Units; Disintegration and Dissolution of Dietary Supplements.
- FDA 21 CFR Part 111—Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements.
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products; ICH Q3D Guideline for Elemental Impurities.
Post time:Oct - 05 - 2025
